Browsing articles in "Unipolar Depression"


Highlights from 2023 NEI Congress: Psychedelics Pre-Conference Workshop
November 9, 2023   

Every year before the official NEI Congress begins, NEI hosts a preconference workshop. Considering that psychedelic medicine has been gaining traction as a viable treatment for mental health disorders, NEI developed this year's preconference workshop to focus on the current landscape of psychedelic medicine.
 Continue reading
Use of LSD On The Rise Among Adults With Depression
October 27, 2023   

Recently, there's been a resurgence in LSD research for mental health treatment. A recent cross-sectional study examined trends in nonmedical...
 Continue reading
Suicide Risk Among Patients Hospitalized With Psychiatric Illness
October 26, 2023   

Fifteen to thirty percent of patients with a history of concussion present with persistent postconcussion symptoms. Individuals with persistent postconcussion symptoms are at greater risk of developing depressive symptoms. In a recent meta-analysis of...
 Continue reading (Members only)
National Depression Screening Day
October 5, 2023   

Like screenings for other illnesses, depression screenings should be a routine part of healthcare. Mood disorders have many symptoms and approaching them clinically involves first constructing a diagnosis from a given patient's symptom profile. An accurate differential diagnosis of depressive illness and other psychiatric comorbidities is needed before the most effective treatment plan can be adopted ...
 Continue reading
FDA Approves Gepirone ER for Treatment of Major Depressive Disorder
September 28, 2023   

The U.S. Food and Drug Administration has approved the resubmission of a New Drug Application for gepirone hydrochloride extended-release (Exxua™) for the treatment of major depressive disorder in adults...
 Continue reading
Suicidal Behavior Among Patients With Major Depressive Disorder
September 19, 2023   

It is well established, as illustrated in the figure above, that abnormalities in the circadian sleep/wake cycle can lead to impairments across a broad spectrum of physiological and mental functions. New research suggests poor sleep may also act as an acute risk factor for suicidal thoughts the next day among young adults already vulnerable to suicide...
 Continue reading (Members only)
Phase 3 Study Finds Subcutaneous Ketamine Safe and Effective in TRD
August 30, 2023   

Major depressive disorder is a significant global health concern, ranking as the second leading cause of disability. Despite multiple attempts with standard treatments, about one-third of individuals with major depression do not experience remission. This condition, known as treatment-resistant depression (TRD), emerges when two or more treatments fail to provide relief. Ketamine has emerged as a novel and effective intervention for TRD due to its rapid action and high efficacy...
 Continue reading (Members only)
Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression
August 24, 2023   

Antidepressants are commonly prescribed to treat acute depressive episodes in bipolar disorder, but their role as maintenance therapy has not been extensively studied. A recent paper published in the New England Journal sought to examine the efficacy of antidepressants as maintenance treatment after the remission of depression...
 Continue reading (Members only)
Role of Neuroactive Steroids and Brain Health
August 9, 2023   

The classic neuropathological hypothesis and treatment basis (e.g., SSRIs, SNRIs, etc) of major depressive disorder has historically centered around monoaminergic dysfunction (e.g., serotonin, norepinephrine, dopamine). More recently, attention is being given to dysfunction in the gamma-aminobutiric acid (GABA) system, with novel treatment developments as a result…
 Continue reading
FDA Approves First Oral Treatment for Postpartum Depression
August 4, 2023   

The U.S. Food and Drug Administration has approved the zuranolone 50 mg for adults with postpartum depression. Zuranolone is the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms for women with postpartum depression (PPD)…
 Continue reading
Top of Page